SigOrgan and Xellar Biosystems Forge Strategic Alliance to Advance AI+BT Innovation in Organoid and Organ-on-a-Chip Technologies

Recently, Signet Therapeutics and Xellar Biosystems signed a strategic cooperation agreement. Both parties will leverage their respective expertise in organoids and organ-on-a-chip fields to engage in in-depth collaboration, jointly committing to the improvement of the organoid and organ chip industry chain and accelerating its industrialization process.

As the world's first targeted cancer drug development company based on organoid disease models and AI technology, SIGNET has successfully constructed a variety of normal tissues including stomach, liver, heart, and tumor organoids with high-frequency mutant genes found in patients. By leveraging its unique organoid disease model + AI platform, the company has demonstrated groundbreaking R&D achievements in difficult-to-treat diseases such as diffuse gastric cancer, ovarian cancer, and triple-negative breast cancer. In particular, using this platform, the company advanced the world’s first targeted drug pipeline for diffuse gastric cancer and other cancer types to Phase I clinical trials (SIGX1094) in just over three years.

Xellar Biosystems is the world's first "3D-Wet-AI" biotechnology company to integrate organ-on-a-chip, high-content three-dimensional (3D) cellular imaging, computer vision (CV), and artificial intelligence (AI) technologies into drug discovery. The company is committed to providing more accurate disease and drug efficacy evaluation models by combining high-throughput organ-on-a-chip technology with cell morphology, multi-omics analysis methods, and AI technologies based on cell morphology. This innovative approach enables Xellar Biosystems to generate 3D cellular images through large-scale organ chips during the drug development process, constructing complex networks of interactions between gene clusters and compound structures, thereby rapidly identifying the most promising drug candidates with significant development potential. Xellar Biosystems has achieved remarkable success in just a few years since its establishment.As the world's only high-throughput organ chip company, the company participates in the OASIS Consortium initiated by the FDA, EPA, and multiple multinational pharmaceutical enterprises, dedicated to developing a new generation of preclinical drug toxicity prediction tools and evaluation systems.By integrating AI technology and multimodal models, Xellar Biosystems is enhancing the efficiency and safety of drug development.The company has established partnerships with well-known pharmaceutical enterprises both in China and abroad, and is expanding collaboration opportunities in the cosmetics and food sectors.In the future, Xellar Biosystems will focus on the development of preclinical models and AI drug screening platforms, expand chip production capacity, promote the industrial application of technology, and benefit patients.

This strategic cooperation will fully integrate the advantages of the two companies in organoid technology and organ-on-a-chip technology. SIGNET will utilize its expertise in front-end organoid biology technology to provide more precise support for disease modeling, new target discovery, and drug screening. Xellar Biosystems, on the other hand, will leverage its expertise in chip engineering technology to promote the efficient application of organoids and chip technology, better recapitulating physiological characteristics. The collaboration between the two parties will not only...Effectively advance the industrialization process of organoid technology and accelerate new drug development., shortening the R&D cycle and bringing more hope and blessings to patients.

SIGNET is the first cancer innovative targeted drug research and development company in China based on organoid disease models + AI. It was initially founded on the Harvard University campus and landed in Shenzhen by the end of 2020, completing nearly 220 million yuan in financing and project funding. The company currently has four drug pipelines. The first pipeline is developing SIGX1094, the world's first targeted drug for diffuse gastric cancer, which has successively obtained IND approvals from the US FDA and China NMPA, received orphan drug designation from the US FDA, and has entered Phase I clinical trials.

SIGNET is not only the phonetic translation of Signet but also adheres to the vision of "full of hope, studying things to gain knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and novel target discovery. Combined with AI-powered screening, synthesis, and optimization of small-molecule compounds, SIGNET develops first-in-class innovative targeted drugs. The company has a 1200-square-meter R&D facility and a 500-square-meter experimental animal housing area. Signet Therapeutics' organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical enterprises in new drug development. Collaborative partners include the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen Borya Pharmaceuticals, and Genuine Biotech, contributing to the birth of more innovative drugs.

Xellar Biosystems was founded in Boston, USA, at the end of 2021. It is the world’s first "3D-Wet-AI" biotech startup to utilize organ-on-a-chip technology combined with high-content three-dimensional (3D) cell imaging, computer vision (CV), and artificial intelligence (AI) for drug discovery and precision medicine research. The founding team of Xellar Biosystems mainly comes from well-known multinational biopharmaceutical companies and top academic institutions such as Harvard University and MIT, bringing extensive experience in industrial pharmaceutical product development and cutting-edge bio-AI technology R&D. Xellar Biosystems is currently the world's only organ-on-a-chip company working alongside the FDA and multinational pharmaceutical alliances to co-develop the next generation of preclinical drug efficacy testing standards based on organ-on-a-chip technology. Xellar Biosystems has established strategic and research collaborations with multiple biopharmaceutical companies and academic institutions.